Nutriband (OTCMKTS: NTRB) is one of 42 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it compare to its competitors? We will compare Nutriband to related companies based on the strength of its profitability, institutional ownership, risk, analyst recommendations, dividends, valuation and earnings.
Institutional and Insider Ownership
45.8% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 46.1% of Nutriband shares are held by insiders. Comparatively, 8.3% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Nutriband and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential downside of 1.53%. Given Nutriband’s competitors higher probable upside, analysts clearly believe Nutriband has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Nutriband and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nutriband Competitors||$1.12 billion||$151.86 million||35.83|
Nutriband’s competitors have higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Nutriband and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. Its product line consists of an energy patch line; a weight management patch line; a multivitamin patch line; a children's multivitamin patch line; an amino acid patch line; an anti-wrinkle patch line; an insect repellant patch line; a detox patch line; a PMS patch line; a sleep patch line; and a nausea and motion sickness patch line. The company was incorporated in 2016 and is headquartered in Orlando, Florida.